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Abstract
Background: Increasing evidence supports carbohydrate restricted diets (CRD) for weight loss
and improvement in traditional markers for cardiovascular disease (CVD); less is known regarding
emerging CVD risk factors. We previously reported that a weight loss intervention based on a
CRD (% carbohydrate:fat:protein = 13:60:27) led to a mean weight loss of 7.5 kg and a 20%
reduction of abdominal fat in 29 overweight men. This group showed reduction in plasma LDL-
cholesterol and triglycerides and elevations in HDL-cholesterol as well as reductions in large and
medium VLDL particles and increases in LDL particle size. In this study we report on the effect of
this intervention with and without fiber supplementation on plasma homocysteine, lipoprotein (a)
[Lp(a)], C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α).
Methods: Twenty nine overweight men [body mass index (BMI) 25–35 kg/m2] aged 20–69 years
consumed an ad libitum CRD (% carbohydrate:fat:protein = 13:60:27) including a standard
multivitamin every other day for 12 wk. Subjects were matched by age and BMI and randomly
assigned to consume 3 g/d of either a soluble fiber supplement (n = 14) or placebo (n = 15).
Results: There were no group or interaction (fiber × time) main effects, but significant time effects
were observed for several variables. Energy intake was spontaneously reduced (-30.5%). This was
accompanied by an increase in protein intake (96.2 ± 29.8 g/d to 107.3 ± 29.7 g/d) and methionine
intake (2.25 ± 0.7 g/d, to 2.71 ± 0.78 g/d; P < 0.001). Trans fatty acid intake was significantly reduced
(-38.6%) while dietary folate was unchanged, as was plasma homocysteine. Bodyweight (-7.5 ± 2.5
kg) was reduced as was plasma Lp(a) (-11.3%). Changes in plasma Lp(a) correlated with reductions
in LDL-cholesterol (r = .436, P < 0.05) and fat loss (r = .385, P < 0,05). At wk 12, both CRP (-8.1%)
and TNF-α (-9.3%) were reduced (P < 0.05) independently of weight loss. IL-6 concentrations were
unchanged.
Conclusion: A diet based on restricting carbohydrates leads to spontaneous caloric reduction and
subsequent improvement in emerging markers of CVD in overweight/obese men who are
otherwise healthy.
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Background
Evidence continues to mount supporting the use of carbo-
hydrate restricted diets (CRD) for weight loss and
improvement in cardiovascular risk [1]. In particular,
CRD have been repeatedly shown to promote weight loss
and improve fasting and postprandial triglycerides, and
plasma HDL-cholesterol (HDL-C), which indicates that
such an approach may be an important treatment option
for the dyslipidemia associated with the metabolic syn-
drome [2]. Also, CRD appear to be particularly effective in
reducing intra-abdominal fat, which is known to correlate
with numerous cardiovascular risk factors [3]. Though tra-
ditional markers of cardiovascular risk are still an integral
part of initial cardiovascular risk assessment, several addi-
tional risk factors have emerged that provide a more com-
plete picture of total risk status.
Elevated plasma levels of the cholesteryl-ester rich lipo-
protein (a) [Lp(a)] increase the risk for development of
cardiovascular disease through both proatherogenic and
prothrombotic properties [4]. Plasma Lp(a) is of particu-
lar interest because of reports that levels are strongly con-
trolled by genetics, and it is generally considered that
standard diet and exercise therapy known to alter plasma
levels of other lipoproteins have little effect on Lp(a) [5],
although intake of dietary trans fatty acids have been
reported to increase concentrations of Lp (a) [6], [7].
However, dietary interventions in which Lp(a) levels were
examined appear to be largely restricted to low-fat diets.
An elevated concentration of homocysteine in plasma is
an independent risk factor for cardiovascular disease that
is treatable through dietary and other interventions [8,9].
Insufficient vitamin B 12 and folate correlate with plasma
homocysteine levels, and supplemental B vitamins and
folate can be part of an effective dietary treatment [4].
However, it is not clear that treatment of hyperhomo-
cysteinemia will reduce cardiovascular disease risk [10].
Consuming a low carbohydrate, high protein diet without
vitamin supplementation has been reported to lead to ele-
vated plasma homocysteine [11].
Inflammatory processes play an integral part in the devel-
opment and exacerbation of atherosclerotic lesions. Hav-
ing an elevated level of the acute-phase reactant C-reactive
protein (CRP) is considered a strong, independent predic-
tor of coronary heart disease [12], and is believed to play
a direct role in the development of atherosclerotic plaque
through effects on the vascular endothelium [13]. A key
precursor to the hepatic production of CRP is interleukin
6 (IL-6). Plasma IL-6 levels can predict the development
of diabetes [14], and is thought to be involved in the
pathogenesis of atherosclerotic vascular disease [15].
Another inflammatory marker involved in both the gener-
ation and propagation of atherosclerosis is tumor necrosis
factor α (TNF-α). TNF-α is thought to be responsible for
endothelial dysfunction [16], thus could also play a role
in atherosclerosis. Most importantly, each of these inflam-
matory markers are elevated in obesity, and can be pro-
duced by adipose tissue [16,17], which underscores the
importance of weight loss in cardiovascular risk manage-
ment.
The purpose of this diet study was to determine the effects
of a 12-wk CRD with and without soluble fiber supple-
mentation in overweight men on plasma levels of homo-
cysteine, Lp(a), CRP, IL-6, and TNF-α. Our hypothesis was
that CRD would improve these emerging risk factors for
CVD.
Methods
Study design
As previously described [18], the study was designed to
investigate the effects of adding a soluble fiber supple-
ment to a CRD on clinical markers of cardiovascular risk
including plasma lipids, glucose, blood pressure, and
body composition. A 12-wk placebo-controlled, double
blind, parallel arm design was used. Subjects were care-
fully matched according to BMI and age, then randomly
assigned to supplement a CRD with 3 g/d of either Kon-
jac-mannan (n = 15) or a placebo (n = 15) containing
maltodextrin and free from Konjac-mannan.
Subjects
A total of 30 men with a BMI between 25 and 35 kg/m2
aged 20–69 years volunteered to participate in the study.
One subject from the fiber group left the study due to mil-
itary obligations. Subjects completed a detailed medical
history questionnaire during subject recruitment. Exclu-
sion criteria were consumption of a CRD (including any
form of purposeful carbohydrate restriction such as the
Atkins diet, South Beach diet, Sugar Busters, and the Zone
diet) or weight loss greater than 2.5 kg in the past 6
months, presence of cardiovascular or thyroid disease or
diabetes mellitus, consumption of lipid lowering pre-
scriptions or supplements, or blood pressure greater than
160/90 mm Hg. At baseline, subject characteristics were:
age, 38.8 ± 14.2 years; body weight, 93.3 ± 14.0 kg; body
fat 32.1 ± 4.4%; and BMI 29.7 ± 3.5 kg/m2. All procedures
were approved by the Institutional Review Board at the
University of Connecticut, and all subjects provided writ-
ten informed consent to participate.
Diet
A detailed description of the experimental diet has been
reported previously [18]. In brief, this was a free-living
study and no food was provided to subjects. Registered
dietitians held group meetings and instructed subjects
how to follow a CRD and how to accurately complete
weighed food records. Each subject received written mate-
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rials to reinforce the principles covered during the meet-
ing. A five-day weighed food record was completed prior
to the intervention and seven-day weighed food records
were completed at weeks 1, 6 and 12. Diet data presented
in the current study is from baseline and wk 12. The diet
was specifically designed to restrict carbohydrates so that
subjects produced ketones detectable in urine. Our previ-
ous work indicates that this requires a carbohydrate intake
of about 10% of total energy. The diet was ad libitum and
no guidelines were given regarding energy consumption.
Subjects were provided with a generic multivitamin/min-
eral to be consumed every-other day. Each tablet provided
the following quantities of select micronutrients: ribofla-
vin 1.7 mg/d; niacin 20 mg/d; B6 2 mg/d; B12 6 µg/d; and
folic acid 400 µg/d. At baseline, subjects were sedentary to
mildly active, and were instructed to maintain baseline
levels of physical activity throughout the intervention.
Data collection
At baseline and wk 12, subjects reported to the laboratory
after an overnight fast. Whole blood was obtained from
an antecubital vein into EDTA tubes, and plasma was
obtained via centrifugation at 1500 × g at 4°C for 20 min.
After plasma was isolated, a preservation cocktail was
added to the samples (5 mL/L aprotinin, 1 mL/L PMSF
and 1 mL/L sodium azide). Plasma was stored in individ-
ual aliquots at -80°C for later analysis. Plasma levels of
homocysteine, Lp(a), CRP, TNF-α, and IL-6 were deter-
mined for baseline and wk 12.
Dietary assessment
Diet records were analyzed using the Nutrition Data Sys-
tem 5.0 (Minneapolis, MN). Analyses were completed to
determine the mean daily intake of kcal and energy con-
tribution from fat, carbohydrate, and protein. Also, mean
daily intake of total folate, and vitamins riboflavin,
niacin, B6, and B12 were determined.
Anthropometrics
Bodyweight was determined on the same calibrated dig-
ital scale to the nearest 100 g with subjects in light cloth-
ing and not wearing shoes. Body composition was
determined using dual-energy X-ray absorptiometry
(Prodigy™, Lunar Corporation, Madison, WI).
Baseline (habitual) energy intake (kcal) vs. change in energy intake from baseline to week 12Figure 1
Baseline (habitual) energy intake (kcal) vs. change in energy intake from baseline to week 12. Mean kcal reduc-
tion from baseline to week 12 (n = 29) was 718 kcal/day. Overweight men consumed a CRD for 12 weeks; r = -.687; P < 0.01.
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Determination of plasma variables
Homocysteine, cysteine, cysteinylglycine
Concentrations of homocysteine, cysteine, and cysteinylg-
lycine in plasma were measured by high pressure liquid
chromatography with fluorometric detection [19] on a
Beckman HPLC system (Fullerton, CA) with refrigerated
autosampler and Jasco FP2020 fluorescence detector
(Tokyo, Japan).
Lp(a)
Plasma Lp(a) was determined in duplicate using a sand-
wich ELISA (#1740–9; Diagnostic Automation, Inc., Cala-
basas, CA, USA) with a dynamic range of 1.0–165 mg/dL.
The intra-assay coefficient of variation (CV) was 9.1%.
Absorbance was determined using a VersaMax tunable
microplate reader with SoftMax® Pro data reduction soft-
ware (Molecular Devices, Sunnyvale, CA, USA).
CRP, IL-6, TNF-α
High-sensitivity CRP was determined in duplicate using a
sandwich ELISA (#30–9710 s; American Laboratory Prod-
ucts Company, Windham, NH, USA). The sensitivity of
the hsCRP assay was 0.124 ng/mL, and the intra-assay CV
was 7.3%. Plasma IL-6 and TNF-α were determined in
duplicate using a high-sensitivity ELISA (#HS600B for
hsIL-6, and #HSTA00C for hsTNF-α; R&D Systems, Min-
neapolis, MN, USA). For the hsIL-6 assay the sensitivity
was 0.039 pg/mL, and the intra-assay CV was 5.2%. For
the hsTNF-α assay the sensitivity was 0.12 pg/mL and the
intra-assay CV was 8.9%. Absorbances were determined
using a VersaMax tunable microplate reader with Soft-
Max® Pro data reduction software (Molecular Devices,
Sunnyvale, CA, USA).
Statistical analyses
Dependent variables were analyzed using a 2 × 2 analysis
of variance with supplement assignment (Fiber and Pla-
cebo) as the between-factor and time (Wk 0 and 12) as the
within factor. Pearson correlation coefficients were used
to determine the relationship between changes in depend-
ent variables. Differences with a P < 0.05 were considered
significant. Data are represented as means ± standard
deviation. Statistical analyses were completed using SPSS
version 12.0 for Windows.
Results
Dietary consumption, bodyweight, and compliance
Compared to the habitual diet, the introduction of a CRD
lead to a decrease in caloric consumption (P < 0.001)
(Table 1) as well as carbohydrate consumption (-73.9%; P
< 0.001), while protein consumption increased (11.5%; P
< 0.05), and fat intake was unchanged at week 12 (4.3%;
P > 0.05). Saturated fat intake was also unchanged (P >
0.05). Habitual energy intake vs. change in energy intake
from baseline to week 12 is plotted in Figure 1. Energy
intake was spontaneously reduced by 718 ± 530 kcal per
day, characterized by a significant reduction in carbohy-
drate intake (-200 ± 64 g/d; P < 0.001) and significant
increase in protein intake (11 ± 27 g/d; P < 0.05), but no
change in fat intake (4 ± 41 g/d; P > 0.05). Thirteen sub-
jects reduced fat intake during the intervention. As
expected by the increase in protein intake, methionine
intake increased significantly. Total folate and vitamin B
12 intake were unchanged (P > 0.05), but vitamin B 6
intake increased (P < 0.001) in comparison to baseline.
Also, by week 12 trans-fat intake was reduced (-37.7%; P
< 0.001). Both bodyweight (-7.5 ± 2.5 kg) and fat mass (-
5.7 ± 2.6 kg) were significantly reduced. There were no sig-
nificant differences between the fiber and placebo groups
for any diet or anthropometric measure. Compliance to
the CRD was high throughout the intervention as deter-
mined through the presence of urinary ketones (data not
shown) and dietary logs.
Plasma homocysteine, cysteine, and cysteinylglycine
Despite increased methionine and unchanged total folate
intake, plasma homocysteine was not significantly
increased (Table 2). Furthermore, plasma cysteine and
Table 1: Changes dietary macro- and micronutrients between habitual and intervention (CRD) diets for 12 weeks in overweight men.
Nutrient Baseline (Habitual) Week 12 of CRD P Value (Time)
Total Energy (kcal) 2350 ± 676 1632 ± 496 < 0.001
Saturated Fat (g) 36.4 ± 16.2 36.8 ± 15.1 > 0.05
MUFA (g) 39.2 ± 15.9 45.2 ± 17.2 > 0.05
PUFA (g) 19.0 ± 7.2 17.9 ± 8.1 > 0.05
Trans Fats (g) 6.1 ± 2.7 3.8 ± 1.8 < 0.001
Methionine (g) 2.2 ± 0.7 2.7 ± 0.8 < 0.01
Total Folate (µg) 434.6 ± 174.1 455.0 ± 121.1 > 0.05
Vitamin B6 (mg) 2.0 ± 1.0 2.7 ± 0.6 < 0.001
Vitamin B12 (µg) 10.1 ± 16.5 11.2 ± 5.3 > 0.05
Data are presented as means ± SD (n = 29). Data were analyzed using a Student's t test. P values refer to the difference between baseline and week 
12. Subjects consumed a CRD supplemented by standard multivitamin consumed every-other day for 12 weeks. MUFA = monounsaturated fatty 
acids; PUFA = polyunsaturated fatty acids. Analysis was performed on 5-day weighed food records for baseline and 7 day weighed food records for 
week 12.
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cysteinylclycine were also unchanged (P > 0.05). No sig-
nificant differences between the fiber and placebo groups
existed.
Plasma lipids and Lp(a)
Mean relative changes for triglycerides, HDL-C, and LDL
cholesterol (LDL-C) for all subjects have been reported
Table 2: Changes in plasma levels of homocysteine, cysteine, and cysteinylglycine from baseline to week 12 in overweight men who 
consumed a CRD.
Parameter Baseline Week 12 P Value (Time)
Homocysteine (µmol/L)
Fiber 8.1 ± 1.2 8.6 ± 2.2 > 0.05
Placebo 8.1 ± 1.4 8.3 ± 1.5 > 0.05
Cysteine (µmol/L)
Fiber 264.4 ± 34.1 258.9 ± 45.3 > 0.05
Placebo 269.0 ± 30.5 266.2 ± 40.7 > 0.05
Cysteinylglycine (µmol/L)
Fiber 30.3 ± 5.1 29.9 ± 4.5 > 0.05
Placebo 30.9 ± 3.8 29.0 ± 5.5 > 0.05
Data are presented as means ± SD for the fiber group (n = 14) and the placebo group (n = 14). P values refer to the difference between baseline 
and week 12. No significant time or treatment effects were observed in any measured plasma marker of homocysteine metabolism. Subjects 
supplemented the CRD by consuming a standard multivitamin every-other day.
Relationship between absolute change in Lp(a) and LDL-C for overweight men who followed a 12-week CRD for weight lossFigure 2
Relationship between absolute change in Lp(a) and LDL-C for overweight men who followed a 12-week CRD 
for weight loss. Changes in Lp(a) and LDL-C are in mg/dL. Subjects were overweight and slightly obese men (n = 29). Calcu-
lations using a Pearson correlation coefficient indicated a relationship (r = .436, P < 0.05).
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previously, and were -34.5%, 12.6%, and -7.0% respec-
tively (P < 0.05) [18]. Plasma Lp(a) was significantly
reduced (-11.7%) from 17.9 ± 10.3 mg/dL at baseline to
15.8 ± 9.2 mg/dL at wk 12. Reductions in plasma Lp(a)
were correlated with reductions in LDL-C (r = .436, P <
0.05; Figure 2) and fat mass (r = .385, P < 0.05), but not
reduction in bodyweight (r = .280, P > 0.05). There were
no differences between the fiber and placebo groups in
Individual responses of Lp(a) for the fiber (left panel) and placebo (right panel) groups from baseline to week 12 for overweight men (n = 29) who consumed a CRDFigure 3
Individual responses of Lp(a) for the fiber (left panel) and placebo (right panel) groups from baseline to week 
12 for overweight men (n = 29) who consumed a CRD. Blue line represents the mean. Lp(a) was significantly reduced 
over time (P < 0.05) with no treatment effects.
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Table 3: Response of plasma markers of inflammation to a CRD in overweight men.
Inflammatory Marker Baseline Week 12 P Value
hsCRP (mg/L)
Fiber 1.68 ± 1.50 1.35 ± 0.95 < 0.05
Placebo 1.86 ± 1.29 1.55 ± 1.23 < 0.05
hsIL-6 (pg/mL)
Fiber 1.31 ± 0.39 1.39 ± 0.50 > 0.05
Placebo 2.00 ± 1.62 1.88 ± 1.07 > 0.05
hsTNF-α (pg/mL)
Fiber 1.29 ± 0.26 1.25 ± 0.30 < 0.05
Placebo 1.18 ± 0.27 1.03 ± 0.27 < 0.05
Data are presented as means ± SD for the fiber group (n = 14) and the placebo group (n = 14). Subjects consumed a CRD supplemented with a 
standard multivitamin consumed every-other day for 12 weeks. P values are for changes over time. No significant treatment effects existed.
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plasma lipids. Twenty-two of 29 subjects had reductions
in plasma Lp(a) at wk 12. Individual changes in Lp(a)
from baseline to week 12 are depicted in Figure 3.
Plasma CRP, IL-6, and TNF-α
Consumption of the CRD and subsequent weight loss led
to significant reductions in hsCRP, and hsTNF-α, but
unchanged hsIL-6, with no significant differences
between groups (Table 3). Individual changes in hsTNF-α,
hsCRP, and hsIL-6 for both the fiber and placebo groups
are shown in Figures 4, 5, and 6, respectively. Changes in
hsCRP and hsTNF-α were not correlated with change in
bodyweight or fat mass (P > 0.05).
Discussion
The purpose of this study was to report observations
about changes in emerging risk factors following weight
loss induced by a CRD with or without soluble fiber sup-
plementation in overweight and slightly obese men.
Though comparisons of these changes cannot be made to
other forms of diet therapy, these data contribute to the
small amount of evidence currently available about the
effects of CRD on markers of CVD risk not traditionally
measured. The main findings of the study were that a CRD
resulted in a spontaneous reduction in caloric intake in
93% of subjects and favorable effects on a number of non
traditional biomarkers including a significant reduction
in plasma Lp(a) in 76% of subjects and a significant
reduction in the inflammatory markers CRP in 69% and
TNF-α in 76% of subjects. There were no effects of adding
additional soluble fiber to a CRD on these responses.
Though dietary fiber has been shown to reduce CVD risk,
it appears that the significant weight loss in our subjects
has overshadowed any potential benefits from the fiber
supplementation.
Consistent with other reports [20-22], simply instructing
subjects to restrict carbohydrates resulted in a spontane-
ous reduction in energy intake (mean 718 kcal/day), sug-
gesting that a CRD may be easier to adhere to than diet
therapies that specifically target energy restriction. The
reduction in caloric intake was predominantly due to the
74% reduction in carbohydrate. There is a common belief
that CRD are high in fat, but in this study the absolute
amount of total fat and saturated fat intake was
unchanged and protein intake only modestly increased.
Homocysteine
Weight loss can lead to increases in homocysteine concen-
trations [23,24], and alter the dose-response relationship
between both serum folate and vitamin B-12 levels (i.e.,
higher serum folate and B-12 levels are required to main-
Individual responses of TNF-alpha for the fiber (left panel) and placebo (right panel) groups from baseline to week 12 for over-we ght men (n = 29) who consumed a CRDFigure 4
Individual responses of TNF-alpha for the fiber (left panel) and placebo (right panel) groups from baseline to 
week 12 for overweight men (n = 29) who consumed a CRD. Blue line represents the mean. TNF-alpha was signifi-
cantly reduced over time (P < 0.05) with no treatment effect.
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tain the same homocysteine level in those losing weight)
[25]. The carbohydrate restricted diet supplemented with
folic acid in this study did not affect homocysteine con-
centrations. This is consistent with other work [26] and a
prior study we published showing that weight loss
induced by a low-fat diet and a 400 µg folic acid supple-
ment resulted in no effect on homocysteine [27]. There-
fore, vitamin supplementation or emphasis on folic acid-
rich foods may be an important component of a weight
loss program to prevent increases in homocysteine.
Homocysteine may be elevated following the ingestion of
a high-protein meal even in individuals accustomed to
higher protein intake. However, homocysteine levels tend
to be normalized following fasting for an extended period
of time (as in preparation for a blood draw) [28]. Post-
prandial measurements were not taken, though any
potential increases in homocysteine appear to have been
transient given the fasting plasma levels.
Lp(a)
Elevated plasma Lp(a) is a risk factor for cardiovascular
disease because of both atherogenic and thrombotic prop-
erties [4]. The 12% decrease in plasma Lp(a) is a novel
finding considering that plasma Lp(a) levels are reported
to have a strong genetic influence [29,30] and that diet
usually has little positive influence on Lp(a) levels [5,31].
Important to note is that most diet interventions that have
examined Lp(a) response emphasized fat restriction with
moderate to high carbohydrate intake, which sharply con-
trasts the macronutrient contribution in the current inter-
vention. Reducing total and saturated fat intake has been
shown to increase Lp(a) during weight maintenance [32]
and have no effect on Lp(a) during weight loss [33]. The
significant decrease in Lp(a) in this study suggests that car-
bohydrate restriction, as opposed to fat restriction, may
play a greater role in modulating Lp(a) levels during
weight loss. Diets relatively high in trans fatty acids in
comparison to saturated or unsaturated fatty acids can sig-
nificantly increase plasma Lp(a) [34]. Thus, the 38%
reduction in trans fatty acid consumption could also have
also influenced this parameter.
Reports about weight loss and change in plasma Lp(a) are
varied. Significant weight loss achieved via a very-low cal-
orie diet in obese individuals has been shown to both
reduce [35] and not reduce plasma Lp(a) [36]. However,
a very-low calorie diet and weight loss may only reduce
plasma Lp(a) in subjects with elevated baseline values (>
20 mg/dL). Our results are in agreement with previous
Individual responses of CRP for the fiber (left panel) and placebo (right panel) groups from baseline to week 12 for overweight men (n = 29) who consumed a CRDFigure 5
Individual responses of CRP for the fiber (left panel) and placebo (right panel) groups from baseline to week 12 
for overweight men (n = 29) who consumed a CRD. Blue line represents the mean. CRP was significantly reduced over 
time (P < 0.05) with no treatment effect.
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reports that reductions in plasma Lp(a) correlate strongly
with baseline Lp(a), but not with weight loss [36,37].
CRP, IL-6, and TNF- α
Both the acute-phase reactant CRP and the inflammatory
cytokine TNF-α were significantly reduced over time.
These results extend our previous findings that weight loss
achieved through carbohydrate restriction can improve
plasma levels of inflammatory biomarkers [38] indicating
that these results persist through 12 wk. Previous reports
[38,39] suggest that weight loss – rather than the macro-
nutrient composition of the diet used to achieve weight
loss – is key to reducing plasma markers of inflammation.
In the present study, a 7.9% weight loss was accompanied
by an 18.5% reduction in CRP, which is consistent with
other reports where low fat [40] and CRD [41] were used
to achieve weight loss. We did not find a correlation
between weight or fat loss and changes in any inflamma-
tory marker. Change in CRP was significantly correlated
with baseline levels, which is similar to a previous report
utilizing a CRD [41]. Another positive alteration in
inflammatory status was the reduction in TNF-α. Obese
individuals release greater quantities of TNF-α, which is at
least partially derived from adipose tissue [42]. The signif-
icant reductions in adipose tissue likely played a role in
reducing plasma TNF-α. As such, it appears that carbohy-
drate restriction could be considered an option for over-
weight men to improve cardiovascular risk.
We also examined the individual data for CRP and TNF-α.
The range for subjects with relative reductions in CRP (n
= 21) was -2.9 to – 71.9%, and the range for subjects with
relative increases in CRP (n = 8) was 1.5 to 43.0%. Four-
teen of 21 subjects who reduced CRP had relative reduc-
tions greater than 20%. Five of eight subjects who had
increases in CRP had elevations greater than 20%. Though
Individual responses of IL-6 for the fiber (left panel) and placebo (right panel) groups from baseline to week 12 for overweight men (n = 29) who consumed a CRDFigure 6
Individual responses of IL-6 for the fiber (left panel) and placebo (right panel) groups from baseline to week 12 
for overweight men (n = 29) who consumed a CRD. Blue line represents the mean. There was no significant time or 
treatment effect for IL-6 (P > 0.05).
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the mean reductions and individual data indicate more
individuals reduced CRP, some individuals had increases,
indicating that weight loss from a CRD may not be univer-
sally appropriate for reducing CRP. However, CRP con-
centrations in individuals who experienced elevations
after 12 wk was 1.36 mg/L (range = 0.14 to 4.17 mg/L),
which is within the normal range. Similarly, 22 subjects
had relative reductions in TNF-α. Our observations indi-
cate that a CRD is generally effective at reducing both CRP
and TNF-α, though, as with any dietary therapy, individ-
ual cases should be evaluated to determine appropriate
treatment.
An unexpected result was that IL-6 was unchanged from
baseline to week 12. IL-6 has often been reported to be
reduced following weight loss [43,44] but not always
[40,45]. IL-6 is thought to be important in the inflamma-
tory cascade associated with atherogenesis because of its
role in both stimulating several cellular adhesion mole-
cules and smooth muscle cell proliferation and migration
[42]. IL-6 also acts as a messenger cytokine [46] and that
derived from adipose tissue is thought to provide the prin-
ciple stimulus for hepatic CRP production [16,42].
Though a considerable amount of plasma IL-6 in healthy
individuals is thought to be derived from adipose tissue
(approximately 30%), a large proportion is derived from
other tissue [47]. Thus, though weight loss – particularly
fat loss – would be expected to reduce plasma IL-6, other
influencing factors likely play an important role.
One potential tissue that may be implicated is skeletal
muscle. It has been reported that consuming a CRD leads
to an approximate 50% reduction in skeletal muscle gly-
cogen [48], which could potentially affect plasma IL-6 lev-
els. Steensberg et al. [49] hypothesized that contracting
skeletal muscle releases IL-6, which acts in a hormone-like
manner to stimulate hepatic glucose output. Subsequent
work indicated that IL-6 release from skeletal muscle is
increased in response to reduced glycogen levels [50]. It is
important to note that reduction of glycogen was accom-
plished through exercise rather that diet. However, the
response of IL-6 to reduced glycogen, taken in conjunc-
tion with observations that infusion of recombinant IL-6
in humans increases liver glucose output [50,51], suggest
a potential explanation for the unchanged IL-6 levels
(despite weight loss) in the present study. Future research
is needed to confirm the role of IL-6 in glycogen depletion
resulting from a CRD.
CRD have been consistently shown to reduce triglycerides
and increase HDL-C, yielding a beneficial effect on CVD
risk, particularly for individuals with metabolic syndrome
[52]. For the current study we correlated triglyceride and
HDL-C responses with emerging risk factors to determine
if plasma lipid responses were related to changes in other
risk factors for CVD. We found no relationship between
response of traditional markers for CVD (HDL-C and trig-
lyceride response) and relative changes in TNF-α, IL-6,
CRP, Lp(a), and homocysteine. As such, we believe that
individuals who have a less favorable triglyceride and
HDL-C response to a CRD do not necessarily have an infe-
rior response in terms of CVD risk markers not tradition-
ally measured.
Conclusion
We have previously reported the beneficial effects of a
CRD on fasting and postprandial plasma lipoproteins and
body composition. Data from this study indicate that the
beneficial effects of a CRD on cardiovascular risk extend
beyond improvements in traditionally measured markers,
and that changes in these emerging biomarkers [Lp(a),
CRP, TNF-α] are not related to the relative response in
plasma triglycerides or HDL-C. These results are limited to
the population of overweight or slightly obese men who
are otherwise healthy. We cannot isolate the specific
aspect of the diet responsible for the responses in emerg-
ing biomarkers, nor can we determine the relative contri-
bution of weight loss versus carbohydrate restriction. An
important finding was that carbohydrate restriction
resulted in a spontaneous decrease in caloric intake and
subsequent weight loss and improvement in several risk
factors for cardiovascular disease in the majority of sub-
jects. Thus, it can be concluded that a diet approach based
on carbohydrate restriction provides an acceptable and
effective model diet to combat obesity and related meta-
bolic disorders.
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